125 related articles for article (PubMed ID: 35059760)
21. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.
Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M
Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878
[TBL] [Abstract][Full Text] [Related]
22. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Amit U; Lawrence YR; Weiss I; Symon Z
Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
[TBL] [Abstract][Full Text] [Related]
24. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
25.
Tran VT; Tu SJ; Tseng JR
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230761
[TBL] [Abstract][Full Text] [Related]
26. MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
Gugliandolo SG; Pepa M; Isaksson LJ; Marvaso G; Raimondi S; Botta F; Gandini S; Ciardo D; Volpe S; Riva G; Rojas DP; Zerini D; Pricolo P; Alessi S; Petralia G; Summers PE; Mistretta FA; Luzzago S; Cattani F; De Cobelli O; Cassano E; Cremonesi M; Bellomi M; Orecchia R; Jereczek-Fossa BA
Eur Radiol; 2021 Feb; 31(2):716-728. PubMed ID: 32852590
[TBL] [Abstract][Full Text] [Related]
27. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
28. Fate of seminal vesicles and prostate after medical castration: how long is the optimal duration of neoadjuvant treatment for prostate cancer before radiation?
Furuya R; Hisasue S; Furuya S; Saitoh N; Ogura H; Takahashi S; Tsukamoto T
Urology; 2008 Aug; 72(2):417-21. PubMed ID: 18267337
[TBL] [Abstract][Full Text] [Related]
29. Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.
Meynard C; Huertas A; Dariane C; Toublanc S; Dubourg Q; Urien S; Timsit MO; Méjean A; Thiounn N; Giraud P
Radiat Oncol; 2019 Dec; 15(1):1. PubMed ID: 31892338
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
Anderson PR; Hanlon AL; Movsas B; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
[TBL] [Abstract][Full Text] [Related]
31. Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness.
Hectors SJ; Cherny M; Yadav KK; Beksaç AT; Thulasidass H; Lewis S; Davicioni E; Wang P; Tewari AK; Taouli B
J Urol; 2019 Sep; 202(3):498-505. PubMed ID: 30958743
[TBL] [Abstract][Full Text] [Related]
32. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
33. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A
Cancer; 2000 May; 88(9):2110-5. PubMed ID: 10813723
[TBL] [Abstract][Full Text] [Related]
34. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
Mendez LC; Martell K; Warner A; Tseng CL; Chung H; Loblaw A; Rodrigues GB; Morton G
Radiother Oncol; 2020 Sep; 150():195-200. PubMed ID: 32619455
[TBL] [Abstract][Full Text] [Related]
35. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of MRI radiomics for high-risk prostate cancer stratification in 1.5 T MR-guided radiotherapy.
Zhou Y; Yuan J; Xue C; Poon DMC; Yang B; Yu SK; Cheung KY
Magn Reson Med; 2023 May; 89(5):2088-2099. PubMed ID: 36572990
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position.
Marnouche EA; Hadadi K; Abdelhak M; Benlemlih M; Hommadi M; Zaghba N; Andaloussi Saghir K; Elmarjany M; Sifat H; Mansouri H
Cancer Radiother; 2021 Apr; 25(2):161-168. PubMed ID: 33454191
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
40. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer.
Abdollahi H; Mofid B; Shiri I; Razzaghdoust A; Saadipoor A; Mahdavi A; Galandooz HM; Mahdavi SR
Radiol Med; 2019 Jun; 124(6):555-567. PubMed ID: 30607868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
